The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Idiopathic Gastroparesis Drugs Market Research Report 2024
Synopsis
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
The global Idiopathic Gastroparesis Drugs market was valued at US$ 3565 million in 2023 and is anticipated to reach US$ 5124.9 million by 2030, witnessing a CAGR of 5.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Idiopathic Gastroparesis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Gastroparesis Drugs.
Report Scope
The Idiopathic Gastroparesis Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Idiopathic Gastroparesis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Idiopathic Gastroparesis Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals
Segment by Type
Prokinetic Agents
Antiemetic Agents
Others
Segment by Application
Hospital Pharmacies
Private Clinics
Drug Stores
E-Commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Idiopathic Gastroparesis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
The global Idiopathic Gastroparesis Drugs market was valued at US$ 3565 million in 2023 and is anticipated to reach US$ 5124.9 million by 2030, witnessing a CAGR of 5.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Idiopathic Gastroparesis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Idiopathic Gastroparesis Drugs.
Report Scope
The Idiopathic Gastroparesis Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Idiopathic Gastroparesis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Idiopathic Gastroparesis Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals
Segment by Type
Prokinetic Agents
Antiemetic Agents
Others
Segment by Application
Hospital Pharmacies
Private Clinics
Drug Stores
E-Commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Idiopathic Gastroparesis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Gastroparesis Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Prokinetic Agents
1.2.3 Antiemetic Agents
1.2.4 Others
1.3 Market by Application
1.3.1 Global Idiopathic Gastroparesis Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Private Clinics
1.3.4 Drug Stores
1.3.5 E-Commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Gastroparesis Drugs Market Perspective (2019-2030)
2.2 Idiopathic Gastroparesis Drugs Growth Trends by Region
2.2.1 Global Idiopathic Gastroparesis Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Idiopathic Gastroparesis Drugs Historic Market Size by Region (2019-2024)
2.2.3 Idiopathic Gastroparesis Drugs Forecasted Market Size by Region (2025-2030)
2.3 Idiopathic Gastroparesis Drugs Market Dynamics
2.3.1 Idiopathic Gastroparesis Drugs Industry Trends
2.3.2 Idiopathic Gastroparesis Drugs Market Drivers
2.3.3 Idiopathic Gastroparesis Drugs Market Challenges
2.3.4 Idiopathic Gastroparesis Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Gastroparesis Drugs Players by Revenue
3.1.1 Global Top Idiopathic Gastroparesis Drugs Players by Revenue (2019-2024)
3.1.2 Global Idiopathic Gastroparesis Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Idiopathic Gastroparesis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Gastroparesis Drugs Revenue
3.4 Global Idiopathic Gastroparesis Drugs Market Concentration Ratio
3.4.1 Global Idiopathic Gastroparesis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Gastroparesis Drugs Revenue in 2023
3.5 Idiopathic Gastroparesis Drugs Key Players Head office and Area Served
3.6 Key Players Idiopathic Gastroparesis Drugs Product Solution and Service
3.7 Date of Enter into Idiopathic Gastroparesis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Gastroparesis Drugs Breakdown Data by Type
4.1 Global Idiopathic Gastroparesis Drugs Historic Market Size by Type (2019-2024)
4.2 Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Type (2025-2030)
5 Idiopathic Gastroparesis Drugs Breakdown Data by Application
5.1 Global Idiopathic Gastroparesis Drugs Historic Market Size by Application (2019-2024)
5.2 Global Idiopathic Gastroparesis Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Idiopathic Gastroparesis Drugs Market Size (2019-2030)
6.2 North America Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Idiopathic Gastroparesis Drugs Market Size by Country (2019-2024)
6.4 North America Idiopathic Gastroparesis Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Idiopathic Gastroparesis Drugs Market Size (2019-2030)
7.2 Europe Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Idiopathic Gastroparesis Drugs Market Size by Country (2019-2024)
7.4 Europe Idiopathic Gastroparesis Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size (2019-2030)
8.2 Asia-Pacific Idiopathic Gastroparesis Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Idiopathic Gastroparesis Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Idiopathic Gastroparesis Drugs Market Size (2019-2030)
9.2 Latin America Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2019-2024)
9.4 Latin America Idiopathic Gastroparesis Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size (2019-2030)
10.2 Middle East & Africa Idiopathic Gastroparesis Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Idiopathic Gastroparesis Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sumitomo
11.1.1 Sumitomo Company Detail
11.1.2 Sumitomo Business Overview
11.1.3 Sumitomo Idiopathic Gastroparesis Drugs Introduction
11.1.4 Sumitomo Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.1.5 Sumitomo Recent Development
11.2 Cadila Pharmaceuticals
11.2.1 Cadila Pharmaceuticals Company Detail
11.2.2 Cadila Pharmaceuticals Business Overview
11.2.3 Cadila Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.2.4 Cadila Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.2.5 Cadila Pharmaceuticals Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Idiopathic Gastroparesis Drugs Introduction
11.3.4 Sanofi Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Idiopathic Gastroparesis Drugs Introduction
11.4.4 Teva Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.4.5 Teva Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Idiopathic Gastroparesis Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Idiopathic Gastroparesis Drugs Introduction
11.6.4 Pfizer Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Kyowa Kirin Pharmaceuticals
11.7.1 Kyowa Kirin Pharmaceuticals Company Detail
11.7.2 Kyowa Kirin Pharmaceuticals Business Overview
11.7.3 Kyowa Kirin Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.7.4 Kyowa Kirin Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.7.5 Kyowa Kirin Pharmaceuticals Recent Development
11.8 Hanmi Pharm
11.8.1 Hanmi Pharm Company Detail
11.8.2 Hanmi Pharm Business Overview
11.8.3 Hanmi Pharm Idiopathic Gastroparesis Drugs Introduction
11.8.4 Hanmi Pharm Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.8.5 Hanmi Pharm Recent Development
11.9 Ani Pharmaceuticals
11.9.1 Ani Pharmaceuticals Company Detail
11.9.2 Ani Pharmaceuticals Business Overview
11.9.3 Ani Pharmaceuticals Idiopathic Gastroparesis Drugs Introduction
11.9.4 Ani Pharmaceuticals Revenue in Idiopathic Gastroparesis Drugs Business (2019-2024)
11.9.5 Ani Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
